Completion of a significant clinical study

Completion of a significant clinical study - Axcellant

Completion of a significant clinical study

  1. lut 01, 2024

Our team at Axcellant is proud to announce the completion of a significant Post-Market Clinical Follow-up study.

This study was meticulously designed to evaluate the performance and safety of a novel wound dressing technology in real-world settings. Emphasizing safety and performance, the study aimed to gather comprehensive data on the expected outcomes and to vigilantly monitor for any expected and unexpected adverse events. The study was completed ahead of schedule.

The success of this study is a testament to the collaborative effort of our dedicated team and the participating medical professionals, who navigated these challenges with expertise and commitment.

If you are interested in any type of medical devices study, please do not hesitate to contact us.

Patrycja Buczak-Kula

Read more

Insights from Turku PET Symposium 2025

Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…

EU regulatory reforms aim to unlock medtech innovation

The EU is moving forward with key upgrades to its medical device and diagnostics regulations, specifically under the Medical Device…

Gene therapy expands beyond oncology — and brings new challenges

Gene therapies now account for most ATMP clinical trials, with a balanced distribution between in vivo and ex vivo approaches.…